Literature DB >> 1301970

The long-term clinical outcome of 56 patients with biopsy-proven lupus nephritis followed at a single center.

R H Derksen1, R J Hené, L Kater.   

Abstract

We retrospectively evaluated the clinical outcome of 45 female and 11 male patients with biopsy-proven lupus nephritis, followed at our hospital between February 1974 and February 1990. In the majority signs of nephritis were present at the time systemic lupus erythematosus was diagnosed (range: -42-156 months) and the median time from onset of nephritis to biopsy was 2 months. The median follow-up from the time of the biopsy was 53.5 months (range: 2-192), the median age at biopsy 25 years and the median serum creatinine level 1.2 mg/dl. Initial renal biopsies had the following histopathological classes according to the World Health Organization criteria (n): I (2); II (10); III (10); IV (28); V (5); VI (1). Over the study period active episodes were treated with high-dose oral prednisone alone or combined with intravenous nitrogen mustard and oral chlorambucil (1974-75), azathioprine (1978-86), cyclophosphamide (1986-90) and/or plasma-exchange (1976-84). These strategies were based on literature data or multicenter studies in which we participated. Eight patients developed end-stage renal disease (ESRD) (median: 47 months post-biopsy; range: 20-120). In these, initial biopsies showed class IV in seven, and class V in one. Confounded risk factors for ESRD were class IV biopsy, male gender and serum creatinine level above 1.4 mg/dl. The calculated proportion without ESRD 5 years post-biopsy was 87% (95% confidence limits: 98-76%), and at 10 years 70% (95% confidence limits: 90-49%). Five patients (11.2%) died; causes of death were cerebrovascular accident (n = 2), cerebral lupus (n = 2) and S. aureus sepsis (n = 1).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1301970     DOI: 10.1177/096120339200100207

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  10 in total

1.  Renal haemodynamic characteristics in patients with lupus nephritis.

Authors:  M Nakano; M Ueno; H Hasegawa; T Watanabe; T Kuroda; S Ito; M Arakawa
Journal:  Ann Rheum Dis       Date:  1998-04       Impact factor: 19.103

2.  Characteristics and influence factors of pathologic transformation in the subclasses of class IV lupus nephritis.

Authors:  Jian-jun Gao; Guang-yan Cai; Shu-wen Liu; Li Tang; Xue-guang Zhang; Yang Yang; Pu Chen; Shu-xin Liu; Jia-yao Ji; Suo-zhu Shi; Zhong Yin; Xiang-mei Chen
Journal:  Rheumatol Int       Date:  2011-03-26       Impact factor: 2.631

Review 3.  Prognosis in systemic lupus erythematosus.

Authors:  J M Esdaile
Journal:  Springer Semin Immunopathol       Date:  1994

Review 4.  Lupus therapy.

Authors:  H Baart de la Faille
Journal:  Clin Investig       Date:  1994-10

5.  Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus.

Authors:  K Manger; B Manger; R Repp; M Geisselbrecht; A Geiger; A Pfahlberg; T Harrer; J R Kalden
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

6.  Predictive value of remission status after 6 months induction therapy in patients with proliferative lupus nephritis: a retrospective analysis.

Authors:  Min Wook So; Bon San Koo; Yong-Gil Kim; Chang-Keun Lee; Bin Yoo
Journal:  Clin Rheumatol       Date:  2011-05-20       Impact factor: 2.980

7.  Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia.

Authors:  Abdurahman Saud Al Arfaj; Najma Khalil; Salman Al Saleh
Journal:  Rheumatol Int       Date:  2009-04-21       Impact factor: 2.631

Review 8.  Treatment of systemic lupus erythematosus: which options do we have for therapy regimens?

Authors:  L Kater; R H Derksen; R J Hené
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

9.  Dysregulated expression of CXCR4/CXCL12 in subsets of patients with systemic lupus erythematosus.

Authors:  Andrew Wang; Philippe Guilpain; Benjamin F Chong; Sandrine Chouzenoux; Loïc Guillevin; Yong Du; Xin J Zhou; Fangming Lin; Anna-Marie Fairhurst; Christopher Boudreaux; Christian Roux; Edward K Wakeland; Laurie S Davis; Frederic Batteux; Chandra Mohan
Journal:  Arthritis Rheum       Date:  2010-11

10.  The renal metallothionein expression profile is altered in human lupus nephritis.

Authors:  Mikkel Faurschou; Milena Penkowa; Claus Bøgelund Andersen; Henrik Starklint; Søren Jacobsen
Journal:  Arthritis Res Ther       Date:  2008-07-06       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.